Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O.

Clin Cancer Res. 2019 Jul 12. doi: 10.1158/1078-0432.CCR-18-4049. [Epub ahead of print]

PMID:
31300450
2.

Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.

Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C, Boyd KL, Summitt IB, Wang LL, Schneider JT, Warner JL, Zhao Z, Lovly CM.

J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463-0. doi: 10.1016/j.jtho.2019.05.042. [Epub ahead of print]

3.

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ.

Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.

PMID:
30867242
4.

Deimplementation of Routine Chest X-rays in Adult Intensive Care Units.

Trumbo SP, Iams WT, Limper HM, Goggins K, Gibson J, Oliver L, Leverenz DL, Samuels LR, Brady DW, Kripalani S.

J Hosp Med. 2019 Feb;14(2):83-89. doi: 10.12788/jhm.3129.

PMID:
30785415
5.

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.

Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, Raymond CK, Horn L, Lovly CM.

J Thorac Oncol. 2019 Mar;14(3):e45-e48. doi: 10.1016/j.jtho.2018.11.031. Epub 2018 Dec 10. No abstract available.

6.

First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.

Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR.

Clin Lung Cancer. 2018 Nov;19(6):531-543. doi: 10.1016/j.cllc.2018.08.011. Epub 2018 Aug 22.

PMID:
30197261
7.

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

Iams WT, Lovly CM.

Cancer Discov. 2018 Jul;8(7):797-799. doi: 10.1158/2159-8290.CD-18-0489.

8.

Fatal massive hemolysis caused by immunoglobulin M anti-c antibody in a patient with newly diagnosed B-cell acute lymphoblastic leukemia: a case report.

Galvez C, Abutaleb A, Iams WT, Lindholm PF, Kwaan HC.

Clin Case Rep. 2018 Apr 17;6(6):1090-1093. doi: 10.1002/ccr3.1534. eCollection 2018 Jun.

9.

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ.

Sci Rep. 2018 Jan 18;8(1):1023. doi: 10.1038/s41598-018-19454-3.

10.

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Chae YK, Galvez C, Anker JF, Iams WT, Bhave M.

Cancer Treat Rev. 2018 Feb;63:116-121. doi: 10.1016/j.ctrv.2017.12.004. Epub 2017 Dec 8. Review.

PMID:
29276997
11.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM.

J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23.

12.

Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.

Iams WT, Villaflor VM.

World J Surg. 2017 Jul;41(7):1719-1725. doi: 10.1007/s00268-017-3959-x. Review.

PMID:
28271259
13.

Novel Targeted Therapies for Metastatic Melanoma.

Iams WT, Sosman JA, Chandra S.

Cancer J. 2017 Jan/Feb;23(1):54-58. doi: 10.1097/PPO.0000000000000242. Review.

PMID:
28114255
14.

Major milestones in translational oncology.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA.

BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y.

15.

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Iams WT, Lovly CM.

Clin Cancer Res. 2015 Oct 1;21(19):4270-7. doi: 10.1158/1078-0432.CCR-14-2518. Review.

16.

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Iams WT, Lovly CM.

Cancer J. 2015 Sep-Oct;21(5):378-82. doi: 10.1097/PPO.0000000000000142. Review.

17.

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA.

Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207.

18.

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM.

Exp Hematol. 2015 Feb;43(2):74-8. doi: 10.1016/j.exphem.2014.10.009. Epub 2014 Oct 28.

19.

Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma.

Tsai JP, Iams WT, Greer JP, Morgan DS, Li S, Reddy NM.

Leuk Lymphoma. 2015 Mar;56(3):797-800. doi: 10.3109/10428194.2014.928937. Epub 2014 Jul 17. No abstract available.

PMID:
24884316

Supplemental Content

Support Center